Peptide Therapy at Longevity Clinics: What's Legal, What Works & What's Next (2026)
Peptide therapy is the fastest-growing treatment category at longevity clinics. But RFK Jr.'s push to reclassify 12 banned peptides has created confusion. Here's which peptides clinics actually use, what the evidence says, what they cost, and how to choose a clinic.
Peptide therapy has become the fastest-growing treatment category at longevity clinics worldwide — and the most politically charged. In April 2026, HHS Secretary Robert F. Kennedy Jr. forced the FDA to schedule a formal review of 12 peptides that the agency banned from compounding pharmacies in 2023, citing safety concerns. PCAC (Pharmacy Compounding Advisory Committee) meetings are set for July 23–24, 2026, with a second round in February 2027.1
The result: a regulatory landscape in flux, a booming gray market (estimated at $328M in 2025),2 and patients who are genuinely confused about what’s legal, what works, and what’s worth paying for.
This guide cuts through the noise. We’ll cover the eight peptides most commonly offered at longevity clinics, grade the evidence, explain the regulatory situation, break down costs, and help you evaluate whether a peptide clinic knows what it’s doing.
For background on the FDA’s 2023 ban and the March 2026 reclassification of 14 other peptides, see our FDA Peptide Reclassification Guide and our Best Longevity Clinics for Peptide Therapy directory.
The 8 Peptides Most Commonly Used at Longevity Clinics
1. BPC-157 (Body Protection Compound-157)
What it is: A 15-amino acid peptide originally isolated from human gastric juice. Promotes angiogenesis (blood vessel formation) and tissue repair.
What clinics use it for: Tendon and ligament injuries, gut healing (ulcerative colitis, leaky gut), joint recovery, anti-inflammatory protocols.
Evidence tier: Moderate preclinical / Limited human. Extensive animal data showing accelerated wound healing, tendon repair, and gut protection. Human data is limited to case reports and small observational studies. No large-scale RCTs published. The FDA lists its potential use as treating ulcerative colitis — but that’s not how most clinics are using it.1
Administration: Subcutaneous injection (most common), oral capsules (lower bioavailability).
Cost at clinics: $200–$600 per month (varies by dose and source).
Regulatory status: Category 2 (restricted from compounding) since 2023. Under PCAC review July 23, 2026.
2. Thymosin Alpha-1
What it is: A naturally occurring peptide that modulates immune function by stimulating T-cell maturation and activity.
What clinics use it for: Immune optimization, chronic infections (Lyme, EBV), autoimmune conditions, cancer adjunctive therapy.
Evidence tier: Moderate. FDA-approved in some countries (not the US) for hepatitis B and C. Published human data for immune modulation. Several clinical trials, including in combination with checkpoint inhibitors for cancer. More evidence than most longevity peptides.
Administration: Subcutaneous injection, typically 2–3x per week.
Cost at clinics: $300–$800 per month.
Regulatory status: Referred to PCAC in September 2024. Status pending.
3. TB-500 (Thymosin Beta-4 Fragment)
What it is: A synthetic fragment of thymosin beta-4 that promotes cell migration, wound healing, and tissue repair.
What clinics use it for: Muscle recovery, tendon/ligament injuries, cardiac tissue repair, anti-inflammatory protocols. Often paired with BPC-157.
Evidence tier: Low–Moderate. Animal data shows promising wound healing and cardiac repair effects. Very limited human clinical data.
Administration: Subcutaneous injection.
Cost at clinics: $250–$600 per month.
Regulatory status: Category 2. Under PCAC review July 23, 2026.
4. GHK-Cu (Copper Peptide)
What it is: A naturally occurring copper-binding peptide that decreases with age. Stimulates collagen production, wound healing, and tissue regeneration.
What clinics use it for: Skin rejuvenation, hair growth, wound healing, anti-aging skin protocols. Applied topically or injected.
Evidence tier: Moderate preclinical / Emerging human. Strong in vitro and animal data on collagen synthesis and tissue repair. Human data mostly from dermatology (topical applications for skin aging). Injectable use at longevity clinics has less published evidence.
Administration: Topical serum, subcutaneous injection, or microneedling.
Cost at clinics: $150–$500 per month (topical); $300–$700 per month (injectable).
Regulatory status: Category 2. Scheduled for PCAC review February 2027.
5. Epitalon
What it is: A synthetic tetrapeptide that activates telomerase — the enzyme that lengthens telomeres (the protective caps on chromosomes that shorten with age).
What clinics use it for: Anti-aging protocols, telomere lengthening, sleep optimization, melatonin regulation.
Evidence tier: Low. Animal studies (primarily Russian research) have shown telomere lengthening and lifespan extension in mice. Human data is extremely limited. The mechanism (telomerase activation) is theoretically compelling but clinically unproven.
Administration: Subcutaneous injection, typically in cycles (10–20 days).
Cost at clinics: $200–$500 per cycle.
Regulatory status: Category 2. Under PCAC review July 23, 2026.
6. MOTS-C
What it is: A mitochondrial-derived peptide that regulates metabolic function, exercise capacity, and glucose metabolism.
What clinics use it for: Metabolic optimization, weight management, exercise performance enhancement, insulin sensitivity.
Evidence tier: Low. Preclinical data shows improved metabolic function and exercise capacity in mice. No published human clinical trials as of early 2026.
Administration: Subcutaneous injection.
Cost at clinics: $250–$500 per month.
Regulatory status: Category 2. Under PCAC review July 23, 2026.
7. Ipamorelin + CJC-1295 (Growth Hormone Secretagogues)
What they are: Peptides that stimulate the pituitary gland to release growth hormone naturally (unlike synthetic HGH, which replaces it directly). Often prescribed together for synergistic effect.
What clinics use them for: Body composition optimization (fat loss, muscle gain), sleep quality, recovery, anti-aging protocols.
Evidence tier: Moderate. Clinical trials exist for both peptides individually. CJC-1295 has demonstrated sustained GH release in healthy adults. More human data than most peptides on this list. Not FDA-approved for longevity indications, but the pharmacological profile is reasonably well-characterized.
Administration: Subcutaneous injection, typically at bedtime (to mimic natural GH pulse).
Cost at clinics: $300–$800 per month (combined protocol).
Regulatory status: Both referred to PCAC in September 2024. Status pending.
8. Semax
What it is: A synthetic peptide derived from ACTH (adrenocorticotropic hormone). Originally developed in Russia for stroke recovery and cognitive enhancement.
What clinics use it for: Cognitive enhancement, neuroprotection, ADHD-like symptoms, stress adaptation.
Evidence tier: Low–Moderate. Approved in Russia and Ukraine for several neurological indications. Russian clinical literature supports cognitive benefits. No FDA-reviewed trials. Western evidence base is thin.
Administration: Intranasal spray (most common), subcutaneous injection.
Cost at clinics: $150–$400 per month.
Regulatory status: Category 2. Under PCAC review July 23, 2026.
The Regulatory Landscape: A Timeline
Understanding peptide regulation at longevity clinics requires tracing the recent history:
| Date | Event | Impact |
|---|---|---|
| Oct 2023 | FDA removes 19 peptides from Category 1 (compounding-allowed) list | Major peptides (BPC-157, TB-500, etc.) banned from compounding pharmacies |
| Sep 2024 | FDA refers 5 peptides to PCAC for review | CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank enter review pipeline |
| Feb 27, 2026 | RFK Jr. announces review of 12 banned peptides | Political pressure on FDA to reverse 2023 restrictions |
| Mar 26, 2026 | HHS announces ~14 peptides reclassified to Category 1 | Key peptides restored for compounding (separate from the 12 under review) |
| Apr 17, 2026 | FDA schedules PCAC meetings for July 23–24, 2026 | 7 peptides (BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon) to be reviewed |
| Feb 2027 | Second PCAC round scheduled | Remaining 5 (GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF) reviewed |
What this means for patients in April 2026: The 14 peptides reclassified in March are legally available through compounding pharmacies with a prescription. The 12 peptides under PCAC review remain in Category 2 (restricted), but enforcement is inconsistent and many clinics continue to offer them through various legal workarounds (research-grade labeling, international sourcing, or physician discretion).
The honest assessment: Patients accessing Category 2 peptides at clinics in 2026 are operating in a regulatory gray zone. The July PCAC meeting may clarify the status of 7 of these peptides, but the process is political as well as scientific. As Public Citizen’s Robert Steinbrook noted: “There is no credible reason to believe that peptides that were deemed unproven or unsafe in 2023 are miraculously safe and effective in 2026.”1 Conversely, clinics argue that the 2023 ban was overly restrictive and that decades of compounding practice supported these peptides’ safety profiles.
How Clinics Administer Peptides
The delivery method matters for both efficacy and the patient experience:
Subcutaneous injection — The gold standard for most peptides. Small insulin-type needle into abdominal or thigh fat. Clinics teach self-administration for home protocols. This is how 80%+ of peptide therapy is delivered at longevity clinics.
Intravenous (IV) — Used for some peptides in clinical settings. Less common for the peptides listed above. More typical for NAD+ or glutathione IVs that clinics often bundle with peptide protocols.
Intranasal — Used for Semax and some cognitive peptides. Convenient but lower systemic bioavailability.
Oral capsules — Available for BPC-157 and a few others. Convenient but significantly lower bioavailability than injectable forms. Best suited for gut-specific applications where oral delivery is actually advantageous.
Topical — Primarily GHK-Cu in serum form for skin applications. Not a systemic treatment.
Cost Comparison Across Clinic Types
| Clinic Type | Monthly Peptide Cost | Protocol Length | What’s Included |
|---|---|---|---|
| US longevity clinics (e.g., 10X Health, Next Health) | $500–$1,500 | 3–6 months | Consultation, prescription, peptides, follow-up labs |
| European longevity clinics (e.g., Progevita, SHA Wellness) | €400–€1,200 | 1–4 weeks residential | Often bundled into residential program pricing |
| Telehealth peptide clinics | $200–$600 | 3–12 months | Prescription + shipped peptides; no in-person diagnostics |
| Direct-to-consumer (gray market) | $50–$200 | Varies | Research-grade peptides, no prescription, no medical oversight |
Important: The cheapest option (DTC gray market) is also the riskiest. Without pharmaceutical-grade compounding, physician oversight, or dose monitoring, patients have no quality assurance. Peptide purity, sterility, and dosing accuracy vary wildly in the unregulated market.
How to Choose a Peptide Therapy Clinic
Not all peptide clinics are equal. Here’s what separates legitimate medical practices from supplement sales operations:
Green flags:
- Physician-directed protocols — peptides prescribed by a licensed MD or DO after diagnostic workup
- Baseline labs before treatment — comprehensive metabolic panel, hormone panel, inflammatory markers
- Regular follow-up and monitoring — not just “here’s your prescription, see you never”
- Transparent pricing — per-peptide or per-protocol pricing, not vague “membership” fees
- Evidence-informed recommendations — clinic explains evidence levels honestly, doesn’t overstate benefits
- Published protocols or physician credentials — verifiable medical expertise in peptide therapy
Red flags:
- No labs required before prescribing — peptides affect multiple systems; baseline data is essential
- Claims of “miracle” results — peptide therapy is adjunctive, not transformative on its own
- Exclusive reliance on research-grade peptides — legitimate clinics use FDA-registered compounding pharmacies
- Pushing 6+ peptides simultaneously — responsible practitioners start with 1–2 targeted peptides and assess response
- No mention of regulatory status — honest clinics disclose which peptides are in regulatory limbo
Clinics in our directory offering peptide therapy:
Several clinics in our directory offer peptide protocols as part of comprehensive longevity programs, including Progevita (Valencia), Next Health (Los Angeles), 10X Health System (Florida), and Fountain Life (multiple US locations). Use our comparison tool to filter by peptide therapy availability and see programs side-by-side.
What to Watch: The July 2026 PCAC Meeting
The July 23–24 PCAC meeting will review 7 peptides including BPC-157, TB-500, MOTS-C, and Epitalon. The outcome will significantly impact the peptide therapy landscape:
- If peptides move to Category 1: Legal compounding access restored, likely price decreases as legitimate pharmacies re-enter the market, and broader clinic adoption with improved quality control.
- If peptides remain Category 2: Current gray market continues, enforcement inconsistencies persist, and the gap between clinic-offered and DTC-accessed peptides widens.
- If the review process is politicized: Concerns have been raised about advisory committee stacking. As Ars Technica reported, watchdogs worry that predetermined outcomes could bypass scientific evaluation.1
We’ll update this guide after the July meeting. Subscribe to our updates or check the clinic directory for the latest.
Medical disclaimer: Peptide therapy is not FDA-approved for longevity indications (unless specifically noted). This article is for informational purposes only and does not constitute medical advice. Consult a physician before starting any peptide protocol.
Footnotes
-
Ars Technica, “RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban.” April 2026. arstechnica.com ↩ ↩2 ↩3 ↩4
-
OnHealthcare.Tech, “The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the Compounding Pharmacy Stack.” April 2026. onhealthcare.tech ↩